Почетна › Многи мијелом › Džordžija › Atlanta
Kliničke studije za Многи мијелом u gradu Atlanta, GA
42 studija za Многи мијелом traži učesnike na lokacijama u gradu Atlanta i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Тражи се учесникФаза 3
- Emory University Hospital Midtown, Atlanta
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Тражи се учесникФаза 1
- Winship Cancer Institute of Emory University, Atlanta
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Тражи се учесникФаза 3
- Emory University - Winship Cancer Institute, Atlanta
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Тражи се учесникФаза 4
- Emory University, Atlanta
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 3
- Emory University, Atlanta
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 2
- Emory University Winship Cancer Institute, Atlanta
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Тражи се учесникФаза 1
- Emory Winchip Cancer Center, Atlanta
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Тражи се учесникФаза 2
- Winship Cancer Institute, Emory University, Atlanta
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Тражи се учесникФаза 1
- Winship Cancer Institute, Emory University, Atlanta
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Тражи се учесникФаза 1/2
- Research Site, Atlanta
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Тражи се учесникФаза 3
- Winship Cancer Institute, Emory University, Atlanta
Collection of Tissue Samples for Cancer Research
Тражи се учесникОпсервациона студија
- Emory University, Atlanta
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 1/2
- Emory University Hospital, Atlanta
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Тражи се учесникФаза 1/2
- Emory University Winship Cancer Center, Atlanta
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Тражи се учесникФаза 1
- The Winship Cancer Institute of Emory University, Atlanta
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Тражи се учесникФаза 3
- Research Site, Atlanta
- Research Site, Atlanta
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Тражи се учесникФаза 1/2
- Winship Cancer Institute of Emory University /ID# 274830, Atlanta
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Тражи се учесникФаза 2/3
- Winship Cancer Institute of Emory University /ID# 277667, Atlanta
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 1/2
- Research Site, Atlanta
CAR T-cell Therapy in Patients With Renal Dysfunction
Тражи се учесникФаза 2
- Caitlin Guzowski, Atlanta
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Тражи се учесникФаза 1/2
- Research Site, Atlanta
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 2
- Winship Cancer Institute of Emory University, Atlanta
- Northside Hospital, Atlanta
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
Тражи се учесникФаза 2
- Emory University (Data Collection Only), Atlanta
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Тражи се учесникФаза 3
- Research Site, Atlanta
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 3
- Emory University, Atlanta
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Тражи се учесникФаза 1
- Winship Cancer Institute Emory University, Atlanta
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Тражи се учесникФаза 1
- Research Site, Atlanta
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 1/2
- Emory University Hospital, Atlanta
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Тражи се учесникФаза 2
- Cancer Treatment Centers of America - Atlanta, Atlanta
- Emory University Winship Cancer Institute, Atlanta
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Тражи се учесникФаза 1/2
- Winship Cancer Institute of Emory University, Atlanta
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Тражи се учесникФаза 2
- Emory University/Winship Cancer Institute, Atlanta
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Тражи се учесникФаза 1
- Emory University Hospital, Atlanta
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Тражи се учесникФаза 3
- Research Site, Atlanta
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Тражи се учесникФаза 4
- Emory University Hospital/Winship Cancer Institute, Atlanta
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Тражи се учесникФаза 1
- Northside Hospital, Atlanta
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Тражи се учесникФаза 1/2
- Emory Winship Cancer Institute, Atlanta
Personalized Autologous Transplant for Multiple Myeloma
Тражи се учесникФаза 1
- Winship Cancer Institute of Emory University, Atlanta
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
Тражи се учесник
- Emory University Hospital/Winship Cancer Institute, Atlanta
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Тражи се учесникФаза 3
- GSK Investigational Site, Atlanta
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Тражи се учесникФаза 1
- Winship Cancer Institute, Atlanta
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Тражи се учесникФаза 1/2
- Emory University Hospital, Atlanta
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Тражи се учесникФаза 1
- Northside Hospital, Atlanta
Studije za Многи мијелом u drugim gradovima
- New York City, NY59 студија
- Boston, MA45 студија
- Houston, TX39 студија
- Durham, NC36 студија
- Nashville, TN31 студија
- Denver, CO26 студија
- St. Louis, MO26 студија
- Rochester, MN25 студија
- Columbus, OH25 студија
- Chicago, IL24 студија
- Milwaukee, WI23 студија
- Baldwin Park, CA23 студија
Ostale studije u gradu Atlanta
- Рак (све врсте)49 студија
- Немалоклетни карцином плућа48 студија
- Рак дојке42 студија
- Рак простате36 студија
- Akutna mijeloidna leukemija30 студија
- Метастатски карцином29 студија
- Рак јајника29 студија
- Колоректални карцином29 студија
- Рак плућа28 студија
- Гојазност26 студија
- Мажорна депресивна поремећеност24 студија
- Затајење срца23 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.